ResMed Inc. $RMD Shares Purchased by Keybank National Association OH

Keybank National Association OH increased its position in shares of ResMed Inc. (NYSE:RMD) by 8.0% during the 4th quarter, Holdings Channel.com reports. The fund owned 139,177 shares of the medical equipment provider’s stock after acquiring an additional 10,346 shares during the period. Keybank National Association OH’s holdings in ResMed were worth $33,524,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. SJS Investment Consulting Inc. lifted its stake in ResMed by 1,433.3% during the 3rd quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 86 shares in the last quarter. WFA of San Diego LLC acquired a new position in ResMed during the 2nd quarter worth about $26,000. Imprint Wealth LLC acquired a new position in ResMed during the 3rd quarter worth about $26,000. ORG Partners LLC lifted its stake in ResMed by 181.6% during the 4th quarter. ORG Partners LLC now owns 107 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 69 shares in the last quarter. Finally, Sunbelt Securities Inc. acquired a new position in ResMed during the 3rd quarter worth about $31,000. Institutional investors and hedge funds own 54.98% of the company’s stock.

Insider Transactions at ResMed

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total value of $450,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michael J. Farrell sold 4,991 shares of the stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $225.50, for a total value of $1,125,470.50. Following the completion of the sale, the chief executive officer directly owned 466,223 shares in the company, valued at $105,133,286.50. This represents a 1.06% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 21,023 shares of company stock worth $5,230,857 in the last ninety days. 0.65% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

RMD has been the topic of several research reports. Stifel Nicolaus increased their target price on ResMed from $260.00 to $265.00 and gave the stock a “hold” rating in a research note on Friday, January 30th. KeyCorp decreased their target price on ResMed from $302.00 to $290.00 and set an “overweight” rating on the stock in a research note on Monday. Wall Street Zen lowered ResMed from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. JPMorgan Chase & Co. started coverage on ResMed in a research report on Wednesday, April 15th. They issued an “overweight” rating on the stock. Finally, Citigroup reduced their price target on ResMed from $345.00 to $340.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, ResMed has a consensus rating of “Moderate Buy” and an average target price of $294.55.

ResMed Price Performance

RMD stock opened at $212.04 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.06 and a quick ratio of 2.32. The firm has a market capitalization of $30.89 billion, a P/E ratio of 20.97, a P/E/G ratio of 1.46 and a beta of 0.93. The business’s 50-day moving average is $234.21 and its two-hundred day moving average is $246.92. ResMed Inc. has a 1 year low of $211.93 and a 1 year high of $293.81.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Friday, January 30th. The medical equipment provider reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. The company had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.40 billion. ResMed had a return on equity of 25.20% and a net margin of 27.53%.ResMed’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.43 EPS. Analysts anticipate that ResMed Inc. will post 11.05 earnings per share for the current fiscal year.

ResMed Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.